Bharat Biotech has given information about its anti-coronavirus nasal vaccine ie nasal vaccine. The company has said that the trial of the second phase of this vaccine is almost complete. which has shown good results. According to Bharat Biotech, this nasal vaccine will help prevent the spread of corona infection.
Giving information about this, Dr. Krishna Eela, Director and Chairman of Bharat Biotech, has also said that permission from the Drug Controller General of India (DCGI) is awaited for the children’s corona vaccine. On the country’s vaccination campaign crossing the figure of 100 crore doses, he said that the collective efforts from the Government of India to the citizens have done a wonderful job in achieving the figure of 100 crore vaccinations.Bharat Biotech’s Covaxine has been recommended for approval by the Subject Expert Committee (SEC) for corona vaccination of all children above two years of age. Bharat Biotech’s Covaccine was first trialed for the vaccination of children. Bharat Biotech completed a three-phase trial of Covaxine on children below 18 years of age. The second and third phase trials of this vaccine were completed in September.
This has allowed the first Zydus Cadila vaccine ZyCoV-D from DCGI to vaccinate adolescents aged 12-18 years. ZyCoV-D will not be given through a syringe or needle. Rather, it will be delivered through an applicator, which will be used for the first time in the country.